documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
19 rows where docket_id = "FDA-2006-N-0304" and posted_year = 2008 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, last_modified, posted_date (date), comment_start_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2006-N-0304-0028 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - American Lung Association, Trends in Asthma Morbidity and Mortality, Epidemiology & Statistics Unit, Research and Program Services, July 2006. | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:08Z | 0 | 0 | 09000064804593a8 | |||
| FDA-2006-N-0304-0024 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 [Article continues in FDA-2006-N-0304-0025] | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:36:51Z | 0 | 0 | 090000648045939c | |||
| FDA-2006-N-0304-0016 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: Analysis completed by FDA based on information provided by IMS Health, IMS National Sales Perspective (TM), 2005, extracted March 2006. These data are available for purchase from IMS Health. Please send all inquiries to: IMS Health, Attn: Brian Palumbo, Account Manager, 660 West Germantown Pike, Plymouth Meeting, PA 19462 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:54Z | 0 | 0 | 0900006480459369 | |||
| FDA-2006-N-0304-0020 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: "Surveillance for Asthma — United States, 1980–1999 -- Malaria Surveillance — United States, 1999," MMWR Morbidity andMortality Weekly Report, 2002 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:59Z | 0 | 0 | 0900006480459377 | |||
| FDA-2006-N-0304-0023 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - References | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:02Z | 0 | 0 | 0900006480459387 | |||
| FDA-2006-N-0304-0022 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 - Continued [Article begins in FDA-2006-N-0304-0027] | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:35:31Z | 0 | 0 | 0900006480459385 | |||
| FDA-2006-N-0304-0027 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 (continued in FDA-2006-N-0304-0022) | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:33:28Z | 0 | 0 | 09000064804593a5 | |||
| FDA-2006-N-0304-0026 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - United Nations Environmental Programme, Production and Consumption of Ozone-Depleting Substances: 1986-2004, 2005 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:06Z | 0 | 0 | 09000064804593a3 | |||
| FDA-2006-N-0304-0025 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 - continued | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:05Z | 0 | 0 | 090000648045939f | |||
| FDA-2006-N-0304-0017 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: Rozek, R.P., and E.R. Bishko, Economics Issues Raised in the FDA's Proposed Rule on Removingthe Essential-Use Designation for Albuterol MDIs, National Economic Research Associates, August 13, 2004 (FDA Docket No. 2003P-0029 C 25) | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:55Z | 0 | 0 | 090000648045936a | |||
| FDA-2006-N-0304-0019 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: U.S. Environmental Protection Agency, The Benefits and Costs of the Clean nAir Act: 1990-2010. (http://www.epa.gov/air/sect812/copy99.html) (November 1999). | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:57Z | 0 | 0 | 0900006480459373 | |||
| FDA-2006-N-0304-0021 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: DeNavas-Walt, C., B.D. Proctor, and C.H. Lee, U.S. Census Bureau, Current Population Reports, P60-229, Income, Poverty, and Health Insurance Coverage in the United States: 2004, p. 18, 2005 | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:26:00Z | 0 | 0 | 0900006480459378 | |||
| FDA-2006-N-0304-0018 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Background Information - Reference: "Chronic Obstructive Pulmonary Disease Surveillance — United States, 1971–2000" MMWR Morbidity and Mortality Weekly Report, CDC | Supporting & Related Material | BKG-Background Material | 2008-12-08T05:00:00Z | 2008 | 12 | 2008-12-08T18:25:56Z | 0 | 0 | 0900006480459371 | |||
| FDA-2006-N-0304-0014 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals, LLC (Graceway) - Addendum to Comment | Other | AMD-Amendment | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2008-12-09T19:09:49Z | 0 | 0 | 0900006480650364 | ||
| FDA-2006-N-0304-0015 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Abbott - Withdrawal | Other | WDL-Withdrawal | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T22:18:53Z | 0 | 0 | 0900006480680030 | ||
| FDA-2006-N-0304-0012 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals, LLC - Request for Extension of Comment Due Date | Other | EXT-Request for Extension Comment Due Date | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T20:44:31Z | 0 | 0 | 09000064804593ad | ||
| FDA-2006-N-0304-0013 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Graceway Pharmaceuticals - Request for Extension of Comment Due Date | Other | EXT-Request for Extension Comment Due Date | 2008-07-21T04:00:00Z | 2008 | 7 | 2008-07-21T04:00:00Z | 2013-07-27T20:44:31Z | 0 | 0 | 09000064804593bc | ||
| FDA-2006-N-0304-0009 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | University of Alabama at Birmingahm (UAB) - Letter | Other | LET-Letter | 2008-06-02T04:00:00Z | 2008 | 6 | 2008-06-02T04:00:00Z | 2008-06-03T00:17:05Z | 0 | 0 | 09000064804593b9 | ||
| FDA-2006-N-0304-0010 | FDA | Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 | Lisa Delaney Correspondence to the Center for Drug Evaluation and Research - Electronic Letter | Other | ELET-Electronic Letter | 2008-06-02T04:00:00Z | 2008 | 6 | 2008-06-02T04:00:00Z | 2008-06-03T00:17:06Z | 0 | 0 | 090000648045aaf8 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;